Hyaluronic acid nanogel

(Development product)

Hyaluronic acid nanogel Pharmaceutical TOP


The Functional Additives Division of Asahi Kaseiʼs Specialty Solutions SBU supplies Ceolus®microcrystalline cellulose to pharmaceutical manufacturers around the world for use as an excipient for drug tablets. This time we have established industrial manufacturing technology for hyaluronic acid (HA) nanogel as a new pharmaceutical excipient, and are providing samples to prospective customers in order to commercialize the product. The commercialization of HA nanogel* would expand the product lineup by adding a drug delivery system (DDS) base material for injection formulations.
*Asahi Kasei has an exclusive license for HA nanogel technology developed by Chugai Pharmaceutical Co., Ltd.


HA nanogel is expected to improve the quality of life (QOL) for patients by enabling the low-toxicity solubilization of insoluble drugs, facilitating the formulation of biopharmaceuticals such as proteins and peptides by suppressing their aggregation and denaturation, and reducing the frequency of injection when repeated administration is required.



HA nanogel is derived by the partial modification of hyaluronic acid with cholesterol. In water, self-association occurs among the cholesterol portions due to hydrophobic interaction, causing the formation of nanometer-scale hydrogel.